Patient- and Caregiver-Reported Impact of Symptoms in Alzheimer Disease, Mild Cognitive Impairment, and Dementia
Individuals with AD, MCI, and dementia experience a variety of symptoms that significantly affect their daily lives. These symptoms, many underrecognized, are of variable importance to individuals with these diseases and may inform potential targets for future therapeutic intervention as well as facilitate the development and validation of disease-specific outcome measures.
Authors
- Jennifer Weinstein (ORCID: https://orcid.org/0000-0002-3984-2120)
- Nuran Dilek (ORCID: https://orcid.org/0000-0001-5800-9022)
- Anika Varma (ORCID: https://orcid.org/0000-0001-9533-7113)
- Jamison Seabury (ORCID: https://orcid.org/0000-0002-8523-509X)
- Abigail Arky (ORCID: https://orcid.org/0000-0001-5833-0553)
- Christine Zizzi (ORCID: https://orcid.org/0000-0001-9382-0806)
- Charlotte Engebrecht (ORCID: https://orcid.org/0009-0002-2982-8197)
- Abigail Mathewson
- Chad Heatwole (ORCID: https://orcid.org/0000-0002-2900-6612)
- Susan Salem‐Spencer
- Spencer Rosero (ORCID: https://orcid.org/0000-0003-1408-8325)
- Elizabeth J. Santos (ORCID: https://orcid.org/0000-0003-1125-4324)
Institutions
- University of Rochester (US)
Publication Details
- Journal
- Neurology Clinical Practice
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1212/cpj.0000000000200418
- Citations
- 3
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- U.S. Department of Defense
- Muscular Dystrophy Association
- Parent Project Muscular Dystrophy
- Novartis Pharmaceuticals Corporation
- Duchenne Research Fund
- Regeneron Pharmaceuticals
- Neurocrine Biosciences
- Acceleron
- Cytokinetics
- AveXis
- Harmony Biosciences
- Astellas Pharma